Coya adds Parkinson’s as disease target for ALS therapy COYA 302

Coya Therapeutics is expanding the pipeline for its COYA 302 immunotherapy, adding two neurodegenerative disorders — frontotemporal dementia (FTD) and Parkinson’s disease — as targets for the amyotrophic lateral sclerosis (ALS) treatment candidate. Brain inflammation is known to drive Parkinson’s — and is a mechanism shared…

MeiraGTx Expanding its Gene Therapy Research for Alzheimer’s and Parkinson’s diseases

MeiraGTx will expand its neurodegenerative disease gene therapy pipeline to include Alzheimer’s disease (AD) and Parkinson’s disease (PD). Recent research has focused on the idea that misfolded proteins play a critical role in damaging neuronal function and progression to neuronal cell death. MeiraGTx’s new program, in partnership with Greg…